Savior Lifetec Corporation

4167

TW0004167002

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
21.2 ^TWD	-2.08%		+1.44%	-5.57%

Mar. 18	Savior Lifetec Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Savior Lifetec Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Pengrui Construction Co. Ltd announced that it expects to receive TWD 240 million in funding from Savior Lifetec Corporation

August 23, 2023

Pengrui Construction Co. Ltd announced it will issue 24,000,000 ordinary shares at a price of NT$10 for the gross proceeds of NT$240,000,000 in a round of funding on August 24, 2023. The transaction involved participation from new investor Savior Lifetec Corporation.

Latest news about Savior Lifetec Corporation

Savior Lifetec Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
Savior Lifetec Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Pengrui Construction Co. Ltd announced that it expects to receive TWD 240 million in funding from Savior Lifetec Corporation	23-08-23	CI
Savior Lifetec Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-04	CI
Savior Lifetec Corporation Announces Executive Changes	23-08-04	CI
Savior Lifetec Corporation Announces Dividend Distribution, Payable August 04, 2023	23-06-19	CI
Savior Lifetec Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Savior Lifetec Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-11	CI
Savior Lifetec Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-05	CI
Savior Lifetec Corporation Appoints as Xu Fang Zhen Head of Internal Audit	22-08-05	CI
Savior Lifetec Corporation and Shenzhen China Resources Gosun Pharmaceutical Co.,Ltd Signs Exclusive Sales Contract for Ertapenem in the Mainland Market	22-06-08	CI
Savior Lifetec Corporation Announces Appointment of Cheng, Chin-Hwa as Member of the Audit Committee	22-06-01	CI
Savior Lifetec Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-04	CI
Savior Lifetec Corporation Approves the Appointment of Cheng, Chin-Hwa as Members of the Compensation Committee	22-04-15	CI
Savior Lifetec Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-11	CI
Savior Lifetec Corporation Announces Demise of Chung, Ping-Hong, Member of Audit Committee and Compensation Committee	22-03-11	CI
EPISTAR Corporation signed a contract to acquire Plant of Savior Lifetec Corporation in Zhunan Science Park from Savior Lifetec Corporation for TWD 610 million.	22-03-02	CI
Savior Lifetec Corporation Announces Change the Representative of Its Legal Person Director, Effective on February 1, 2022	22-01-28	CI
Savior Lifetec Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-03	CI
Savior Lifetec Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-05	CI
Savior Lifetec Corporation Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-18	CI
Savior Lifetec Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-04	CI
Savior Lifetec Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-12	CI
Savior Lifetec Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-03	CI
Savior Lifetec Corporation Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-16	CI

Chart Savior Lifetec Corporation

Duration

Period

More charts

Company Profile

SAVIOR LIFETEC CORPORATION is a Taiwan-based company principally engaged in the development, manufacture and distribution of antibiotic bulk pharmaceutical chemicals and intermediates. The Companyâs products portfolio mainly consists of Meropenem and Imipenem/Cilastatin, Meropenem as well as Ertapenem, among others, which are used as spectrum antibiotics. In addition, it is involved in the provision of APIs intermediates as well as bio-pharmaceutical technology services. The Company distributes its products to Europe, the Americas, Asia and other markets.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SAVIOR LIFETEC CORPORATION	-5.57%	206M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.62%	43.34B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B
SANDOZ GROUP AG	+10.86%	14.09B
CIPLA LIMITED	+13.07%	13.64B
ZYDUS LIFESCIENCES LIMITED	+37.46%	11.43B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B